Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 3481 - 3488 of 12094 results

Beyond Extenders: What Might the “Blue Wave” Mean for Renewables Tax Legislation? (Part Two)
January 25, 2021| News

President Biden's Immigration Plan Legalizes Millions of Undocumented Workers
January 22, 2021| News

Private Capital Marketplaces & IPOs
January 21, 2021| Video| Viewpoint

Preparation for 2020 Fiscal Year-End SEC Filings and 2021 Annual Shareholder Meetings
January 21, 2021| Advisory| Viewpoint

HIPAA Amendments and Other Trump Regulatory Actions on Hold
January 21, 2021| Blog| Viewpoint

The Automatic Stay: Supreme Court Finds that Retaining Debtors’ Property, Despite Turnover Demands, is Not a Stay Violation
January 21, 2021| Blog| Viewpoint

Substantial AML Reforms Enable Regulators to “Follow the Money”
January 21, 2021| Blog| Viewpoint

Unions Wade Into Debate Over Requiring COVID-19 Vaccine
January 21, 2021| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
